Moomoo AI 已提取核心訊息
On February 12, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This amendment is intended to convert the existing registration statement into a registration statement on Form S-3 and to remove from registration the Convertible Note Shares that were previously registered, of which 230,494 have been sold. The company also announced a primary offering of up to 8,923,935 shares of common stock upon the exercise of warrants and a secondary offering of up to 9,850,363 shares of common stock and up to 2,411,848 warrants. The warrants, exercisable at $11.50 per share, include Public Warrants, Private Warrants, and Convertible Note Warrants. ProSomnus, a manufacturer of oral appliance therapy devices for obstructive sleep apnea, will not receive proceeds from the sale of securities by the Selling Securityholders, except for potential proceeds from the exercise of warrants. The company's common stock and public warrants are listed on the Nasdaq under the symbols 'OSA' and 'OSAAW,' respectively.
On February 12, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This amendment is intended to convert the existing registration statement into a registration statement on Form S-3 and to remove from registration the Convertible Note Shares that were previously registered, of which 230,494 have been sold. The company also announced a primary offering of up to 8,923,935 shares of common stock upon the exercise of warrants and a secondary offering of up to 9,850,363 shares of common stock and up to 2,411,848 warrants. The warrants, exercisable at $11.50 per share, include Public Warrants, Private Warrants, and Convertible Note Warrants. ProSomnus, a manufacturer of oral appliance therapy devices for obstructive sleep apnea, will not receive proceeds from the sale of securities by the Selling Securityholders, except for potential proceeds from the exercise of warrants. The company's common stock and public warrants are listed on the Nasdaq under the symbols 'OSA' and 'OSAAW,' respectively.
2024年2月12日，特拉華州的一家公司ProSomnus, Inc. 向美國證券交易委員會（SEC）提交了S-3表格S-1的生效後修正案。該修正案旨在將現有的註冊聲明轉換爲S-3表格的註冊聲明，並將先前註冊的可轉換票據股票從註冊中刪除，其中230,494股已出售。該公司還宣佈在行使認股權證時首次發行最多8,923,935股普通股，並二次發行最多9,850,363股普通股和最多2,411,848份認股權證。認股權證可按每股11.50美元的價格行使，包括公開認股權證、私人認股權證和可轉換票據認股權證。ProsomNUS是阻塞性睡眠呼吸暫停的口服器械治療設備的製造商，除行使認股權證的潛在收益外，不會獲得出售證券持有人出售證券的收益。該公司的普通股和公開認股權證分別在納斯達克上市，代碼分別爲 “OSA” 和 “OSAAW”。
2024年2月12日，特拉華州的一家公司ProSomnus, Inc. 向美國證券交易委員會（SEC）提交了S-3表格S-1的生效後修正案。該修正案旨在將現有的註冊聲明轉換爲S-3表格的註冊聲明，並將先前註冊的可轉換票據股票從註冊中刪除，其中230,494股已出售。該公司還宣佈在行使認股權證時首次發行最多8,923,935股普通股，並二次發行最多9,850,363股普通股和最多2,411,848份認股權證。認股權證可按每股11.50美元的價格行使，包括公開認股權證、私人認股權證和可轉換票據認股權證。ProsomNUS是阻塞性睡眠呼吸暫停的口服器械治療設備的製造商，除行使認股權證的潛在收益外，不會獲得出售證券持有人出售證券的收益。該公司的普通股和公開認股權證分別在納斯達克上市，代碼分別爲 “OSA” 和 “OSAAW”。
有用
沒用